SELLAS Life Sciences to Present at Two Upcoming February Investor Conferences
February 06 2018 - 8:30AM
- BIO CEO & Investor Conference on February
13 -- RBC Capital Markets Healthcare Conference on February 21
-
SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS),
a development-stage biopharmaceutical company focused on novel
cancer immunotherapies for a broad range of cancer indications,
today announced that Angelos Stergiou, M.D., ScD h.c., President
and Chief Executive Officer of SELLAS, will present a corporate
overview at the following upcoming conferences.
- BIO CEO & Investor Conference 2018Date:
Tuesday, February 13, 2018Presentation Time: 2:30 PM ETLocation:
New York Marriott Marquis, New York, NY
- 2018 RBC Capital Markets Healthcare
ConferenceDate: Wednesday, February 21, 2018Presentation
Time: 2:35 PM ETLocation: Lotte New York Palace Hotel, New York,
NY
A live webcast of each presentation can be accessed on the
investor page of SELLAS’ website
at www.sellaslifesciences.com/investors. A replay of
each webcast will also be archived for up to 30 days on SELLAS’
website following the conference.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a development-stage
biopharmaceutical company focused on novel cancer
immunotherapeutics for a broad range of cancer indications. SELLAS'
lead product candidate, galinpepimut-S (GPS), is a cancer
immunotherapeutic agent licensed from Memorial Sloan Kettering
Cancer Center that targets the Wilms Tumor 1 (WT1) protein, which
is present in an array of tumor types. GPS has potential as a
monotherapy or in combination to address a broad spectrum of
hematologic cancers and solid tumor indications. GPS is Phase
3-ready for two indications, acute myeloid leukemia (AML) and
malignant pleural mesotheliomia (MPM), and is also in development
as a potential treatment for multiple myeloma and ovarian cancer.
SELLAS plans to study GPS in up to four additional indications.
SELLAS recently received Orphan Drug designations from the U.S.
Food & Drug Administration (FDA), as well as the European
Medicines Agency, for GPS in AML and MPM; GPS also received Fast
Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSellas Life Sciences
Group813-864-2571info@sellaslife.com
Source: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024